Shenzhen - Delayed Quote CNY

Shanghai Xuerong Biotechnology Co.,Ltd. (300511.SZ)

6.66
+0.18
+(2.78%)
At close: May 23 at 3:04:16 PM GMT+8
Loading Chart for 300511.SZ
  • Previous Close 6.48
  • Open 5.68
  • Bid 6.64 x --
  • Ask 6.65 x --
  • Day's Range 6.50 - 7.14
  • 52 Week Range 2.40 - 7.14
  • Volume 97,487,628
  • Avg. Volume 54,641,432
  • Market Cap (intraday) 3.777B
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) --
  • EPS (TTM) -1.24
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 14, 2021
  • 1y Target Est --

Shanghai Xuerong Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research and development, industrial planting, and sale of fresh edible mushrooms in the People's Republic of China. It offers shiitake, shiji, king oyster, velvet, antler, and shiitake mushrooms, as well as Pleurotus eryngii and Flammulina velutipes. The company was formerly known as Shanghai Gaorong Food Co., Ltd. Shanghai Xuerong Biotechnology Co., Ltd. was founded in 1997 and is headquartered in Shanghai, the People's Republic of China.

www.xuerong.com

2,112

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300511.SZ

View More

Performance Overview: 300511.SZ

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300511.SZ
91.93%
SSE Composite Index (000001.SS)
0.10%

1-Year Return

300511.SZ
72.09%
SSE Composite Index (000001.SS)
7.44%

3-Year Return

300511.SZ
1.83%
SSE Composite Index (000001.SS)
6.40%

5-Year Return

300511.SZ
42.91%
SSE Composite Index (000001.SS)
19.00%

Compare To: 300511.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300511.SZ

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    3.78B

  • Enterprise Value

    5.50B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.82

  • Price/Book (mrq)

    3.20

  • Enterprise Value/Revenue

    2.75

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -30.77%

  • Return on Assets (ttm)

    -2.53%

  • Return on Equity (ttm)

    -48.75%

  • Revenue (ttm)

    2B

  • Net Income Avi to Common (ttm)

    -615.07M

  • Diluted EPS (ttm)

    -1.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    44.78M

  • Total Debt/Equity (mrq)

    164.71%

  • Levered Free Cash Flow (ttm)

    280.89M

Research Analysis: 300511.SZ

View More

Company Insights: 300511.SZ

Research Reports: 300511.SZ

View More

People Also Watch